Skip to main content

Part of Ovarian Cancer Audit Feasibility Pilot (OCAFP) - Profile and treatment report

Data download

Previous Chapter

References

Current Chapter

Current chapter – Data download

View all

Page contents

Introduction

This workbook contains data on incidence, mortality, stage, survival and treatment of patients with ovary, fallopian tube and primary peritoneal carcinomas in England. These data are part of the Ovarian Cancer Audit Feasibility Pilot.

The Ovarian Cancer Audit Feasibility Pilot is a collaboration between the gynaecological oncology clinical community, the charity sector and NHS England to perform meaningful analysis of routinely collected data for the purposes of improving care and outcomes for women diagnosed with ovarian cancer in England. The Ovarian Cancer Audit Feasibility Pilot is jointly funded by The British Gynaecological Cancer Society, Target Ovarian Cancer and Ovarian Cancer Action and is being delivered by analysts at the National Cancer Registration and Analysis Service, which is now part of NHS England. 

Content overview

The data workbook contains the following tables:

Tables

Title and content

Table 1

Crude and age-standardised incidence rates, stratified by year of diagnosis (2001 to 2019)

Table 2

Crude and age-standardised incidence rates for the period 2015 to 2019, stratified by geography (Cancer Alliance, ICB and sub-ICB)

Table 3

Crude and age-standardised mortality rates for the period 2015 to 2019, stratified by geography (Cancer Alliance, ICB and sub-ICB)

Table 4

Counts of tumours diagnosed during the period 2015 to 2019, stratified by registry stage and geography (Cancer Alliance, ICB and sub-ICB)

Table 5

Age-standardised one-year and five-year net survival for patients diagnosed during the period 2015 to 2019, stratified by geography (NHS Region, Cancer Alliance, ICB) and reported with and without borderline tumours

Table 6

Rolling one-year and five-year age-standardised net survival for patients diagnosed during the period 2001 to 2019, reported with and without borderline tumours 

Table 7

Tumour characteristics and patient demographics of ovarian cancer patients, excluding those with borderline disease (diagnosed 2019)

Table 8

Tumour characteristics and patient demographics of the analytical cohort, excluding stage 1 and borderline disease (diagnosed 2019)

Table 9

Variation in receipt of any treatment versus no treatment, stratified by Cancer Alliance and excluding stage 1 and borderline disease (diagnosed 2019)

Table 10

Variation in receipt of any treatment versus no treatment, stratified by tumour characteristics and patient demographics, excluding stage 1 and borderline disease (diagnosed 2019)

Table 11

Variation in receipt of any surgery versus no surgery, stratified by Cancer Alliance and excluding stage 1 and borderline disease (diagnosed 2019)

Table 12

Variation in receipt of any surgery versus no surgery, stratified by tumour characteristics and patient demographics, excluding stage 1 and borderline disease (diagnosed 2019)

Table 13

Variation in receipt of any chemotherapy versus no chemotherapy, stratified by Cancer Alliance and excluding stage 1 and borderline disease (diagnosed 2019)

Table 14

Variation in receipt of any chemotherapy versus no chemotherapy, stratified by tumour characteristics and patient demographics, excluding stage 1 and borderline disease (diagnosed 2019)

Table 15

Variation in receipt of primary surgery with adjuvant chemotherapy versus neoadjuvant chemotherapy and interval debulking surgery, stratified by Cancer Alliance and excluding stage 1 and borderline disease (diagnosed 2019)

Table 16

Variation in receipt of primary surgery with adjuvant chemotherapy versus neoadjuvant chemotherapy with interval debulking surgery, stratified by tumour characteristics and patient demographics, excluding stage 1 and borderline disease (diagnosed 2019)

Table 17

Maximally-adjusted geographic variation in any treatment, surgery and chemotherapy, stratified by Cancer Alliance (diagnosed 2019)

Table 18

Annual rates of treatment between 2015 and 2019, excluding stage 1 and borderline disease

Table 19

Age-adjusted variation in any treatment, surgery and chemotherapy for tumours diagnosed between 2015 and 2019, stratified by Cancer Alliance, excluding D391 and borderline disease

Table 20

Probability of age-adjusted variation in any treatment, surgery and chemotherapy for tumours diagnosed between 2015 and 2019, stratified by tumour characteristics and patient demographics, excluding D391 and borderline disease

Table 21

Comorbid conditions and scoring applied for the derivation of a Charlson comorbidity score

Table 22

List of major surgical resection codes

Download

Please select the box below to download the data tables:

(All content in the workbook is available under the Open Government Licence (OGL) v3.0, except where otherwise stated.)

Last edited: 25 May 2023 11:53 am

  1. Ovarian Cancer Audit Feasibility Pilot (OCAFP) - Profile and treatment report
  2. Introduction
  3. Ovarian Cancer Audit Feasibility Pilot Steering Group
  4. Incidence
  5. Mortality
  6. Stage
  7. Survival
  8. Treatment variation by stage, age, tumour morphology and Charlson comorbidity score
  9. Treatment variation by Cancer Alliance
  10. Conclusion
  11. Appendix 1 - Cohort definitions
  12. Appendix 2 - Stage
  13. Appendix 3 - Defining geographies
  14. Appendix 4 - Survival methodology
  15. Appendix 5 - Variables defined for the treatment variation analysis
  16. Appendix 6 - Statistical analysis for geographic variation in treatment
  17. Appendix 7 - Glossary
  18. Appendix 8 - Useful links
  19. Appendix 9 - Comments on impact from the BCGS membership
  20. References
  21. Data download